<DOC>
	<DOC>NCT01472614</DOC>
	<brief_summary>This is an open clinical study for 12 weeks of therapy to investigate clinical efficacy and safety of an add-on therapy with DLBS3233 in improving blood glucose control, lipid profile, and adiponectin in subjects with type-2 diabetes mellitus.</brief_summary>
	<brief_title>Efficacy and Safety of Add-on Therapy With DLBS3233 in Patients With Type-2 Diabetes Mellitus</brief_title>
	<detailed_description>There will only be one group in this study who will receive study treatment as follows: anti-diabetic agents currently used by respective subjects for at least 3 months prior to Screening, treatment intensification (lifestyle modification), and DLBS3233 at a dose of 100 mg once daily for 12 weeks. Clinical and laboratory examinations to evaluate the investigational drug's efficacy and safety will be performed at baseline and at interval of 6 weeks over the 12-week course of therapy.</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<criteria>Male subjects with age of 40 70 years; or female subjects with age of 55 70 years (postmenopause) at screening Diagnosed with type2 diabetes mellitus Have been being treated with a combination of two OHA for at least 3 months prior to screening A1c level of &gt;= 7.0 % Hemoglobin level of &gt;= 10 g/dL Body Mass Index (BMI) &gt; 18.5 kg/m2 Refuse insulin therapy Able to take oral medicine Subjects with symptomatic congestive heart failure, unstable angina pectoris, or cardiac arrhythmia Uncontrolled hypertension defined as systolic blood pressure &gt; 160 mmHg and/or diastolic blood pressure &gt; 100 mmHg History of or current chronic treatment with insulin History of renal and/or liver disease Impaired liver function: serum ALT &gt; 2.5 times upper limit of normal and positive result of chronic or acute hepatitis B or C test Impaired renal function: serum creatinine &gt;= 1.5 times upper limit of normal Current treatment with systemic corticosteroids or herbal (alternative) medicines Any other disease state or uncontrolled illness, which judged by the investigator, could interfere with trial participation or trial evaluation Participation in any other clinical studies within 30 days prior to screening</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>Type-2 diabetes mellitus</keyword>
	<keyword>Add-on therapy</keyword>
</DOC>